Abstract
Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.
Original language | English |
---|---|
Pages (from-to) | 1059-1065 |
Number of pages | 7 |
Journal | Future Oncology |
Volume | 12 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2016 Apr |
Bibliographical note
Publisher Copyright:© 2016 Future Medicine Ltd.
Keywords
- carcinoid tumors
- gastroenteropancreatic tumors
- intertumor heterogeneity
- intratumor heterogeneity
- neuroendocrine tumors
- targeted agents
ASJC Scopus subject areas
- Oncology
- Cancer Research